Neurodegenerative and Cognitive Consequences of Long COVID.

Publication date: Aug 01, 2026

The SARS-CoV-2 virus has infected approximately 778 million people worldwide since the pandemic. Patients who have survived coronavirus disease (COVID-19) may experience long-term symptoms related to cognitive deficits, mood changes, and depressive disorders. The mechanisms underlying the long-term effects of COVID-19 on the brain are being actively investigated. SARS-CoV-2 infection triggers various mechanisms, such as hyperstimulation of the immune response, which may lead to changes in the central nervous system. In this article, we review the evidence linking COVID-19 to neurodegenerative disorders and cognitive impairment. Current research indicates that patients with pre-existing cognitive and neuropsychiatric deficits have a poorer prognosis after SARS-CoV-2 infection, and patients who have survived COVID-19 may be at increased risk of developing dementia and mood disorders. We analyse the available evidence regarding SARS-CoV-2 brain infection, induction of inflammation, coagulopathy, and blood-brain barrier (BBB) dysfunction as possible mechanisms underlying the disorders in the acute phase of COVID-19 disease and contributing to the development of neurodegenerative disorders in long COVID. Viral infection can trigger inflammation of the central nervous system (CNS), leading to damage and contributing to the development of cognitive dysfunction.

Open Access PDF

Concepts Keywords
Coagulopathy Blood-Brain Barrier
Coronavirus Cognitive Dysfunction
Dementia cognitive impairment
Lead COVID-19
Pandemic COVID-19
Humans
Neurodegenerative Diseases
neurodegenerative diseases
Post-Acute COVID-19 Syndrome
SARS-CoV-2

Semantics

Type Source Name
disease MESH Long COVID
pathway KEGG Coronavirus disease
disease MESH COVID-19
disease MESH depressive disorders
pathway REACTOME SARS-CoV-2 Infection
disease MESH neurodegenerative disorders
disease MESH cognitive impairment
disease MESH dementia
disease MESH mood disorders
disease MESH infection
disease MESH inflammation
disease MESH Viral infection
disease MESH Sexually Transmitted Diseases
drug DRUGBANK Coenzyme M
pathway REACTOME Neurodegenerative Diseases
disease MESH cytokine storms
drug DRUGBANK Angiotensin II
disease MESH interstitial pneumonia
disease MESH acute respiratory distress syndrome
disease MESH syndrome
disease MESH CRS
pathway REACTOME Apoptosis
disease MESH lung injury
disease MESH fatigue
disease MESH relapse
disease MESH anosmia
disease MESH anxiety
pathway REACTOME Immune System
disease MESH neuroinflammation
pathway KEGG Viral replication
disease MESH hypoxia
drug DRUGBANK Cefaclor
disease MESH CCL
drug DRUGBANK Uric Acid
drug DRUGBANK Oxygen
disease MESH NOD
pathway REACTOME Inflammasomes
disease MESH death
disease MESH Brain inflammation
disease MESH infarcts
drug DRUGBANK Thrombin
drug DRUGBANK Fibrinogen Human
drug DRUGBANK Serotonin
drug DRUGBANK L-Tryptophan
disease MESH psychiatric disorders
disease MESH necrosis
disease MESH thrombocytopenia
disease MESH ischaemic stroke
disease MESH stroke
disease MESH insomnia
disease MESH psychotic disorders
disease MESH hallucinations
disease MESH memory deficits
disease MESH confusion
disease MESH catatonia
disease MESH autoimmune encephalitis
disease MESH obsessive compulsive disorder
disease MESH included
disease MESH posttraumatic stress disorder
disease MESH muscle weakness
disease MESH brain fog
disease MESH Alzheimer’s disease
disease MESH Parkinson’s disease
disease MESH headache
disease MESH overweight
disease MESH obesity
disease MESH CNS infections
disease MESH neurological manifestation
pathway REACTOME Mitophagy
disease MESH brain disorders
disease MESH mitochondrial dysfunction
pathway REACTOME Cellular Senescence
drug DRUGBANK Dopamine
drug DRUGBANK L-Tyrosine
disease MESH cardiovascular disease
disease MESH renal failure
drug DRUGBANK Water
disease MESH respiratory diseases
disease MESH sleep disorders
disease MESH chest pain
disease MESH musculoskeletal pain
disease MESH gastrointestinal diseases
disease MESH hematemesis
disease MESH gastrointestinal cancers
drug DRUGBANK Tocilizumab
disease MESH pneumonia
disease MESH cancer
disease MESH coronavirus infections
disease MESH Dis
drug DRUGBANK Guanosine
disease MESH injury
drug DRUGBANK Bismuth subgallate
disease MESH severe acute respiratory syndrome
disease MESH Leukemia
disease MESH Fibrosis
pathway KEGG Wnt signaling pathway
drug DRUGBANK ATP
pathway KEGG Tight junction
disease MESH Park
disease MESH MOGAD
disease MESH Rai
disease MESH Mota
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Ketamine
disease MESH Treatment resistant depression
drug DRUGBANK Trestolone
drug DRUGBANK Sodium hydroxide
disease MESH cognitive symptoms
disease MESH influenza
disease MESH Neurocognitive Disorder
disease MESH bipolar disorder
disease MESH neurological disorders
disease MESH Fahn

Original Article

(Visited 7 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *